



Treatment Failure Rate of Penicillin Gas Empiric Therapy for Pediatric Community-Acquired Pneumonia in Children Admitted in Gov. Celestino Gallares Memorial Hospital

Catherine Grace Q Aparece and Anabella S Oncog*

Department of Pediatrics, Gov. Celestino Gallares Memorial Hospital, Philippines

*Corresponding Author: Anabella S Oncog, Department of Pediatrics, Gov. Celestino Gallares Memorial Hospital, Philippines.

Received: November 11, 2019; Published: November 27, 2019

DOI: 10.31080/ASPE.2019.02.0186

Abstract

Background: Pneumonia remains the leading cause of death among children under five. Antibiotic therapy is the mainstay of treatment for children with pneumonia requiring hospitalization. Empiric penicillin therapy has been recommended by the Philippine Academy of Pediatric Pulmonologists, Inc. (PAPP). There has been no local study yet on the treatment failure or cure rate of penicillin therapy in pediatric community acquired pneumonia (PCAP).

Objective of the study: To determine the failure rate of penicillin therapy among children with community acquired pneumonia admitted to Gov. Celestino Gallares Memorial Hospital (GCGMH).

Methodology: This is a prospective descriptive study on children 2 to 59 months old who were admitted to the pediatric wards of GCGMH for PCAP. Approval to conduct the study was granted by the hospital institutional review board. All eligible children were followed up from admission to discharge. Data gathered included clinicodemographic profile like age, gender, duration of breastfeeding, primary caregiver's educational level, smoker in the household, family member with cough, and nutritional status; change of antibiotic from penicillin to another antibiotic because of treatment failure. Descriptive statistics were used to determine the clinicodemographic profile of patients treated with penicillin G. Chi-square test for association was performed to determine the relationship between clinicodemographic profile and treatment failure of penicillin G. Significance was confirmed for p-value of <0.05.

Results: There was a total of 277 patients with PCAP who were admitted to GCGMH from November 1, 2018 to April 30, 2019. Most of these patients were infants 12 months and younger and were males. More than 75% of these children were breastfed longer than 3 months. Only 1 of these patients received less than 3 doses of pneumococcal conjugate vaccine and Hemophilus influenzae type b vaccine. Majority of these children's primary caregivers attained secondary education level. A smoker in the household was present in 96.4% of cases and a household contact with cough was present in 97% of cases. More than half of the cases were well-nourished and 2.89% had severe wasting. Eleven percent of these children did not respond favorably to penicillin and therapy was changed to another antibiotic. Correlation tests between the clinicodemographic profile of patients and their response to penicillin G showed that there is a positive correlation only between nutritional status and response to penicillin G (p-value <0.009).

Conclusion: The failure rate of penicillin G therapy in children hospitalized with community acquired pneumonia is 11%. Only the child's nutritional status impacts the response to penicillin G. Children with severe wasting are less likely to respond favorably to penicillin G compared to children who are better nourished.

Keywords: GCGMH; Children; Penicillin G

Introduction

Pneumonia remains the leading cause of death among children under five, killing approximately 2,400 children a day. It accounted for approximately 16% of the 5.6 million under-five deaths, killing around 880,000 children in 2016 [1].

It was estimated that more than 150 million episodes of pneumonia occur annually in under five years age group in developing nations [2]. The Philippines, a developing country in the Western Pacific Region, has an estimated incidence rate of pneumonia in children less than 5 years of age of 110 per 1000 person-years [3]. It is one of the 15 countries that together account for 75% of childhood pneumonia cases worldwide [4].

Local statistics have shown that pneumonia is a major cause of pediatric morbidity in this hospital. In 2017, it topped the leading causes of morbidity. There were 1659 cases of PCAP-C, making up 38% of the total pediatric discharges.

Antibiotic therapy is the mainstay of treatment for children with pneumonia requiring hospitalization. The choice of antibiotics for hospitalized children with community-acquired pneumonia is usually empiric, based on clinical and radiologic findings and knowledge of the etiology of the pneumonia at different ages.

Pneumonia etiology varies by age, underlying conditions, geographic location, vaccine exposure and seasonality. An accurate etiologic diagnosis is often complicated and differentiating between bacterial and nonbacterial pneumonia is clinically difficult. Current evidence suggests severe pneumonia results from infection with multiple pathogens such as bacterial-viral, dual viral, or mycobacterial-bacterial infections [5]. It has been reported that up to a third of children with pneumonia may have viral-bacterial co-infections [6].

Streptococcus pneumoniae and *Hemophilus influenzae* type b (Hib) are the two principal causes of pneumonia. *Streptococcus pneumoniae* causes up to 18% of severe cases and 33% deaths, followed by Hib that causes 4% of severe episodes and 16% of deaths, and finally, by influenza virus that causes 7% of severe episodes and 11% of deaths [7]. The predominance of *Streptococcus pneumoniae* and Hib is common in both developed and developing countries. In Tanzania, a study showed that *Streptococcus pneumoniae* topped the list of microbiological findings in children with

pneumonia, followed by Hib [8]. A study conducted in Cambodia also showed a high frequency of *Hemophilus influenzae* and *Streptococcus pneumoniae* [9]. A Finnish study conducted in 2012 also revealed that *Streptococcus pneumoniae* and *Hemophilus influenzae* were the most common bacteria in children with community-acquired pneumonia [10].

The risk of pneumonia and of pneumonia hospitalization has been shown to be associated with age, maternal history of pneumonia, cigarette smoking, and a crowded household [11]. Additional risk factors were also reported by Bersam., *et al.* and these include maternal education <8 years, child's birth order, and prenatal complications [12]. Malnutrition has also been consistently shown to be a risk factor for pneumonia [13-16].

The Philippine Academy of Pediatric Pulmonologists (PAPP), Inc., a society of pediatric pulmonologists in the country, came up with a revision of the 2004 Clinical Practice Guidelines (CPG) on pediatric community acquired pneumonia on 2016. The revisions were mostly on the criteria for the risk classification for pneumonia-related mortality. The guidelines remained steadfast on the recommendation that for patients who have been classified as PCAP C without previous antibiotic and have completed the primary immunization against *Hemophilus influenzae* type b, penicillin may be given [17].

This recommendation to give penicillin as empiric therapy for community-acquired pneumonia in children has been based on several studies. One of the studies was conducted by Dinur-Schejter, *et al.* in 2013. They compared treatment failure and the number of patients who were febrile and who required oxygen 72 hours after admission between patients who were given penicillin or ampicillin and patients who were given cefuroxime. They found out that there was no significant difference in these endpoints between the two groups. Thus, they concluded that in previously healthy children, parenteral penicillin or ampicillin for treatment of non-complicated community-acquired pneumonia is as effective as cefuroxime and should remain as first-line therapy [18].

Another study was conducted by Amarilyo., *et al.* in 2014. In this study, they hypothesized that community-acquired pneumonia requiring parenteral medication can still be cured with penicillin G. After a prospective, randomized study comparing low-dose penicillin G, high-dose penicillin G, and intravenous cefuroxime,

they found out that the children recovered at the same rate with no significant difference in time to defervescence or duration of hospitalization. They concluded that penicillin G is as effective and safe as cefuroxime for community acquired pneumonia in otherwise healthy children, even in moderate doses [19].

The effectivity of penicillin monotherapy has also been demonstrated in a study conducted in Kenya. The authors compared the effectiveness of penicillin to that of a combination of penicillin and gentamicin in children characterized by indrawing. They concluded that there was no statistical difference in the treatment of indrawing pneumonia with either penicillin or penicillin plus gentamicin [20].

The department of pediatrics of Gov. Celestino Gallares Memorial Hospital (GCGMH) has followed the guidelines since their dissemination. In fact, the department has long been using penicillin following the World Health Organization program for the control of acute respiratory infections [21].

The hospital antibiogram in the last half of 2017 specific for pediatric patients, unfortunately has not been able to show a significant proportion of *Streptococcus pneumoniae* and *Hemophilus influenzae*. Hence, the antibiogram could not be used as basis for empiric therapy of pneumonia in pediatric patients. Moreover, no local study has recently been conducted yet on the treatment failure or cure rate of penicillin therapy in pediatric community acquired pneumonia; thus, this study was proposed.

Significance of the study

This study is believed to benefit the following stakeholders:

- **Philippine Pediatric Society (PPS), Inc.:** This study will provide local data that will either fortify or refute the recommendations in the guidelines.
- **Gov. Celestino Gallares Memorial Hospital:** This research, which has application in both local and national setting, supports the institution's vision and mission of becoming a premier research facility in region VII.
- **Resident Trainees of the Department of Pediatric Medicine:** Inasmuch as the present guidelines are not the absolute word in the management of children with community acquired pneumonia and are not based on local studies, the out-

put of this research will supersede the recommendations and will serve as a solid basis for their choice of antibiotic in the management of pediatric community acquired pneumonia.

- **The Boholano Children:** The output of this study will benefit the Boholano children because this promotes and supports rational use of antibiotics; hence, preventing injudicious use of the more expensive higher-generation antibiotics, and consequently limiting the rise of antibiotic resistance.

Objectives of the Study

General objective

To determine the failure rate of penicillin therapy among children with community-acquired pneumonia admitted to Gov. Celestino Gallares Memorial Hospital.

Specific objectives

- To determine the proportion of patients admitted to Gov. Celestino Gallares Memorial Hospital for community-acquired pneumonia and treated empirically with penicillin G
- To determine the clinico-demographic profile of patients treated with penicillin G
- Age
- Gender
- Duration of breastfeeding
- Primary caregiver's educational level
- Smoker in the household
- Family member with cough
- Nutritional status
- To determine the proportion of patients who failed to respond favorably to penicillin G and whose therapy was shifted to other antibiotics
- To determine the association between clinicodemographic profile and treatment failure of penicillin G

Definition of terms

- **Pneumonia:** For the purpose of this study, pneumonia refers to pediatric community-acquired pneumonia (PCAP) – C based on the PAPP criteria for the risk classification for pneumonia-related mortality[17].

- **Community-acquired pneumonia:** An acute pulmonary infection in a previously healthy individual acquired in the community
- **Treatment failure:** Absence of improvement, i.e., persistence of fever, tachypnea, dyspnea, or hypoxemia, after at least 48 hours of antibiotic therapy or deterioration of patients, i.e., development of pneumothorax, pneumatocele, pleural effusion, respiratory failure, or sepsis, during antimicrobial therapy [22].

This will be reflected in the data as non-responder to penicillin G.

- **Responder:** This refers to patients who responded favorably to penicillin G. This will be mainly manifested as resolution of fever and tachypnea.
- **Nutritional status:** The nutritional status of patients will be reflected as the degree of wasting noted on admission.

Methodology

Research design

This is a prospective descriptive study.

Study population and locale

This study included all children 3 to 59 months old who are admitted to the pediatric wards of Gov. Celestino Gallares Memorial Hospital for pediatric community-acquired pneumonia.

Inclusion criteria

- Children 3 to 59 months old with signs and symptoms of pneumonia acquired in pre-hospital setting
- Penicillin G was the empiric therapy started on admission.

Exclusion criteria

- Children with chronic lung disease
- Children with cardiac disease: those with known cardiac lesions, or those with incidental finding of murmur on admission
- Children with bronchial asthma
- Children given intravenous antibiotic other than Penicillin G for more than 24 hours.

Duration of the study

Data gathering commenced on November 1, 2018 and ended on April 30, 2019.

Sampling technique

This study utilized total population enumeration.

Data gathering procedure

- The researchers sought the approval of the research proposal from the hospital Institutional Review Board (IRB).
- After IRB approval was obtained, the researchers wrote to the chief of hospital through the head of the IRB to ask permission to access the charts of patients who were eligible for inclusion in the study.
- A waiver of informed consent was duly filled up.
- After all the appropriate permissions were granted, the researcher gathered the necessary data from the patient's charts in the ward.
- The researcher followed the patients included in the study from the day of admission to the day of discharge.
- The researcher noted down the hospital number, patient's clinicodemographic profile, the length of penicillin therapy or change of antibiotic from penicillin to another antibiotic because of treatment failure.

Statistical analysis

Descriptive statistics were used to determine the clinicodemographic profile of patients treated with penicillin G. These included construction of frequency and percentage distribution tables. Chi-square test for association was performed to determine the relationship between clinicodemographic profile and treatment failure of penicillin G of the patients. Significance was confirmed for p-value <0.05. All data analyses were performed using Statistical Package for Social Science (SPSS) version 20.0.

Results

There was a total of 277 patients with community-acquired pneumonia who were admitted and who were included in the study.

Based on the data shown in Table 1, most of the PCAP patients who were treated with Penicillin G were infants 12 months and younger and were males. More than 75% of these children were breastfed longer than 3 months. Only 1 of these patients received less than 3 doses of pneumococcal conjugate vaccine and Hemophilus influenzae type b vaccine. Majority of these children's primary caregiver attained secondary education level. A smoker in the household was present in 96.4% of cases and a household contact with cough was present in 97% of cases. More than half of the cases of children with PCAP were well-nourished, and 2.89% of cases had severe wasting.




Figure 1: Percentage Distribution of Patients with PCAP Based on Response to Penicillin G.

Eighty-nine percent of PCAP patients responded favorably to Penicillin G, and 11% were non-responder to Penicillin G.

Correlation tests between the clinicodemographic profile of PCAP patients and their response to Penicillin G showed that there is a positive correlation between nutritional status and the response to Penicillin G, which was highly significant with p-value of 0.009 ($r = |0.200|$). There was no correlation noted between the response to Penicillin G and age, gender, duration of breastfeeding, pneumococcal and H. influenzae immunization status, educational level of the primary caregiver, presence of smoker in the household as well as presence of household contact with cough.

Clinic demographic Profile	Frequency	Percentage
Age		
3 - 12 months	185	66.79%
13 - 59 months	92	33.21%
Gender		
Male	164	59.21%
Female	113	40.79%
Duration of breast feeding		
< 3 months	62	22.38%
> 3 months	215	77.62%
Pneumococcal immunization status		
< 3 doses	1	0.36%
3 doses	276	99.64%
Hemophilus influenzae type B immunization status		
< 3 doses	1	0.36%
3 doses	276	99.64%
Primary caregiver's education level		
Primary	10	3.61%
Secondary	242	87.36%
Collegiate	24	8.66%
Post graduate	1	0.36%
Smoker in the household		
Present	267	96.39%
Absent	10	3.61%
Household contact with cough		
Yes	270	97.47%
No	7	2.53%
Nutritional status of patients		
Well - nourished	167	60.29%
Mild wasting	72	25.99%
Moderate wasting	30	10.83%
Severe wasting	8	2.89%

Table 1: Clinicodemographic Profile of Patients with PCAP and Treated with Penicillin G.

Clinicodemographic Profile	Response to Penicillin		p-value	r
	Responder	Non-responder		
Age			0.134	0.09
3 - 12 months	168	17		
13 - 59 months	78	14		
Gender			0.523	0.038
Male	144	20		
Female	102	11		
Duration of breast feeding			0.627	0.029
< 3 months	54	8		
> 3 months	192	23		
Pneumococcal immunization status			0.722	0.021
< 3 doses	1	0		
3 doses	245	31		
Hemophilus influenzae type B immunization status			0.722	0.021
< 3 doses	1	0		
3 doses	245	31		
Primary caregiver's education level			0.464	0.096
Primary	9	1		
Secondary	217	25		
Collegiate	19	5		
Post graduate	1			
Smoker in the household			0.253	0.069
Present	236	31		
Absent	10	0		
Household contact with cough			0.34	0.057
Yes	239	31		
No	7	0		
Nutritional status of patients			0.009	0.200
Well - nourished	155	12		
Mild wasting	57	15		
Moderate wasting	28	2		
Severe wasting	6	2		

Table 2: Association Between Clinicodemographic Profile and Response to Penicillin G.

Discussion

Pneumonia remains one of the leading causes of morbidity in Gov. Celestino Gallares Memorial Hospital. Hospital statistics

showed that there were 562 children who were admitted for pneumonia from November 1, 2018 to April 30, 2019. Of these, 277 children (49.2%) were given penicillin G as empiric therapy.

This study showed that more than 2/3 of the children admitted for pneumonia were infants aged 3 to 12 months. This finding is similar to that reported in the study of Le Roux., *et al.* who followed mother-infant pairs in Paarl, South Africa up to 1 year of age. They found out that pneumonia is high in the first year of life in this South African birth cohort despite strong immunization program that included 13-valent pneumococcal conjugate vaccine [23]. This finding is indirectly similar to an old study by Leowski who estimated from data from 39 countries that there are more deaths per year from pneumonia among infants 0 – 1 year old (2.6 million) than among children 1 to 4 years old (1.4 million) [24].

This study showed that more male than female children were admitted for pneumonia. Le Roux's study also showed that the male sex is one of the strongest risk factors for pneumonia. This may possibly be because of gender-related differences in immune or inflammatory responses [25,26], or differences in lung structure or function [27]. Casimir, *et al.* showed in their study of 482 children that the median C-reactive protein concentration in girls was significantly higher than in males, i.e., 5.45 mg/dL vs. 2.6 mg/dL ($p < 0.0001$); the median erythrocyte sedimentation rate was also significantly higher in female children than in male children, i.e., 39.5 mm/h vs. 24 mm/h ($p < 0.005$); and the median neutrophil count was also significantly higher for girls than for boys, i.e., 8796 cells/uL vs. 6774 cells/uL ($p < 0.02$) [25]. A study conducted by Yang, *et al.* on mice identified a critical role for estrogen-mediated activation of lung macrophage nitric oxide synthase-3 (NOS-3), thus explaining why females are more able to fend off pneumonia. The role of estrogen was affirmed when treating the male mice with estrogen resulted in a boost in their immune system's ability to kill off bacteria in their lungs [28].

This study showed that more children who were breastfed longer than 3 months were admitted for pneumonia. This seems to contradict the finding of Bersam., *et al.* who reported that breastfeeding >3 months is a protective factor against pneumonia [11], and the systematic literature review and meta-analysis conducted by Lamberti., *et al.* in 2013 that highlighted the protective effects of breastfeeding against pneumonia incidence, prevalence, hospitalizations, mortality and all-cause hospitalizations and mortality in children under 2 years old [29]. Furthermore, the study by Le Roux., *et al.* also showed that breastfeeding duration was not a significant factor affecting the incidence of pneumonia in children [23].

An overwhelming majority of children admitted for pneumonia had completed the primary series of the pneumococcal and the Hemophilus influenza b (Hib) vaccines. This finding contradicts the reports touting the effectiveness of these vaccines. In a meta-analysis of 6 randomized trials, it was shown that the efficacy of pneumococcal conjugate vaccine (PCV) for preventing vaccine-type invasive pneumococcal disease (IPD) in children <2 years of age was 80% [30]. The effectiveness of PCV in preventing IPD in children <5 years old is confirmed by dramatic declines in the incidence of IPD after routine infant immunization was introduced [31,32]. Similarly, the Hib conjugate vaccines have been shown to have virtually eliminated invasive Hib disease in the United States and in other countries that routinely immunize infants against Hib [33,34]. So if 99.64% of the children admitted for pneumonia had complete doses of the primary series of the PCV and Hib vaccines, then questions like vaccine failure or non-vaccine serotype etiologies may probably arise. Furthermore, a hospital-based case control study conducted on children 1 to 59 months old with pneumonia in Brazil did not show the expected protective effect of the pneumococcal vaccine, suggestive of the multiple etiology of pneumonia, or pneumonia caused by nonvaccine serotypes [35].

Majority of the children who were admitted for pneumonia had mothers who reached secondary level of education. This finding is consistent with that reported by Bersam., *et al.* i.e., maternal education <8 years is a risk factor for pneumonia [11]. Other studies have also reported that low educational levels of mothers are a major risk factor for pneumonia in children under 5 years of age [23,35,36]. This may possibly be related to lack of or inadequate knowledge on pneumonia. The authors think that this may be a venue that needs to be addressed in order to prevent pneumonia or mitigate the morbidity and mortality from pneumonia.

Ninety-six percent of the children admitted for pneumonia lived in a household which has a resident smoker. Exposure to cigarette, especially if the mother smokes, has been reported to increase the risk of pneumonia in infants younger than 1 year old [37]. Le Roux also reported that maternal smoking is one of the strongest risk factors for pneumonia [23]. A study conducted in Mexico even reported that children exposed to environmental tobacco smoke has more than threefold increased risk of developing pneumonia [38]. This may be because cigarette smoke compromises natural pulmonary defense mechanisms by disrupting both mucociliary function and macrophage activity [39].

Exposure to a household contact with cough was apparent in the majority of children admitted for pneumonia. This highlights the transmission of the etiologic agents through air-borne droplets from a cough or sneeze [40] and the critical role of the observance of at least the cough etiquette [41] in the reduction of transmission of the causative agents of pneumonia.

More than half of the children admitted for pneumonia were well-nourished, and a quarter of the subject population were mildly wasted. Severely wasted children accounted for only 2.89% of cases. This finding differs from that of Rahman., *et al.* who reported that respiratory illnesses with fever or cough were more frequent in Bangladeshi children with moderate or severe wasting [42]. Severe underweight was also seen to have a positive association with pneumonia incidence in South African infants [23]. Similarly, 25% of Kenyan children who were admitted for severe pneumonia were severely undernourished [43]. The authors can only postulate that the significant deviation of the finding in this study from that of published articles may be attributed to the sampling methodology. This study included only pneumonia patients treated empirically with penicillin. Severely wasted patients tend to have more severe pneumonia that require more aggressive empiric antibiotic use, thus were excluded from the study.

Majority of the children admitted for pneumonia responded favorably to penicillin. Only 11% of them required change to a second line antibiotic for apparent non-responsiveness. This finding is similar to the result of the study conducted by Simbalista., *et al.* who reported that penicillin G successfully treated 82% of children hospitalized for community-acquired pneumonia. They further reported that children in the penicillin G group showed marked improvement of symptoms, including fever, tachypnea, chest indrawing, and nasal flaring [44]. In relation to this, comparative studies between penicillin which is a narrow-spectrum antibiotic and cephalosporins like cefuroxime, cefotaxime and ceftriaxone which are broad-spectrum antibiotics showed that penicillin is as effective as the broad-spectrum antibiotics [18,19,45,46]. The results of all these studies suggest that penicillin should remain the first choice of therapy for children hospitalized with pneumonia.

Correlational studies between the clinicodemographic features of the subject population and the response to penicillin showed that all the clinicodemographic features, except the nutritional status, have no effect on response to penicillin. These findings

differ from the findings in the studies by Addobo-Yobo., *et al.* and Tiewsoh., *et al.* who demonstrated that younger age, breastfeeding, and immunization status, as well as previous use of antibiotics, overcrowded home, and higher respiratory rate are independent predictors of possible treatment failure [47,48].

This study showed that only the nutritional status of the patient is related to response to penicillin. This indicates that the severely wasted patients are less likely to respond to penicillin as compared to the better nourished patients.

Several studies have shown how malnutrition can increase the frequency and severity of infectious diseases. However, the author could not find any article that fully explains how malnutrition promotes treatment failure of penicillin in community-acquired pneumonia. One factor that may explain the higher therapeutic failure rate of penicillin in severely wasted children is that *Streptococcus pneumoniae* has been found to be a less frequent etiology of community-acquired pneumonia in severely malnourished patients. In a systematic review on pneumonia in severely malnourished children in developing countries conducted by Chisti., *et al.* it was demonstrated that *Streptococcus pneumoniae* accounted for only 18% of all cases of pneumonia in severely malnourished children. Overall, the most commonly isolated organisms in severely malnourished children with pneumonia were, in decreasing frequency, *Klebsiella* species (26%), *Staphylococcus aureus* (25%), *Streptococcus pneumoniae* (18%), *Escherichia coli* (8%), *Hemophilus influenzae* (8%), and *Salmonella* species (5%). The remaining proportion consists of other organisms like *Acinetobacter* species, *Pseudomonas* species, *Moraxella* species, and *Enterobacter* species [49].

Treatment failure in severely malnourished children hospitalized for pneumonia may also be due to superinfection [50] or nosocomial bacteremia [51]. In a study in Kilifi District Hospital in Kenya, it was reported that severe malnutrition was significantly associated with nosocomial bacteremia, with a hazard ratio of 2.52. The authors defined nosocomial bacteremia as bacteremia that occurred after 48 hours or more of admission. Thus, empiric penicillin therapy may fail as it is a narrow spectrum antibiotic and will not be effective against organisms causing nosocomial infection.

Conclusion

The failure rate of Penicillin G therapy in children hospitalized with community-acquired pneumonia is 11%. Only the child's nu-

tritional status impacts the response to Penicillin G. Children with severe wasting are less likely to respond favorably to Penicillin G compared to children who are better nourished.

Recommendations

Based on the results of this study, the author recommends that:

1. Penicillin G should remain the first-line antibiotic therapy for children with community-acquired pneumonia.
2. Clinicians caring for children with severe wasting may have the option to use a wide-spectrum antibiotic to treat community-acquired pneumonia.
3. A prospective study to determine the causative agents of bacteremia in severely malnourished children may be conducted in order to provide local data that will guide empiric therapy for community-acquired pneumonia in severely malnourished children.

Bibliography

1. United Nations Children's Fund. UNICEF Data: Monitoring the situation of children and women (2018).
2. Rudan I., *et al.* "Global estimates of the incidence of clinical pneumonia among children under five years of age". *Bull World Health Organization* (2004): 895-903.
3. Fischer Walker CL., *et al.* "Global burden of childhood pneumonia and diarrhoea". *The Lancet* 381. 9875 (2013): 1405-1416.
4. World Health Organization (WHO) Philippines. Focus on pneumonia (2014).
5. Zar HJ., *et al.* "Pneumonia in low and middle countries: progress and challenges". *Thorax*, 68 (2013): 1052-1056.
6. Walker CL., *et al.* "Global burden of childhood pneumonia and diarrhea". *Lancet* 381(2013): 1405-1416.
7. Caggiano S., *et al.* "Factors That Negatively Affect the Prognosis of Pediatric Community-Acquired Pneumonia in District Hospital in Tanzania". *International Journal of Molecular Sciences* 18 (2017): 623.
8. Vong S., *et al.* "Acute lower respiratory infections >5 year-old hospitalized patients in Cambodia, a low-income tropical country: clinical characteristics and pathogenic etiology". *BMC Infectious Diseases* 13, (2013): 97.
9. Honkinen M., *et al.* "Viruses and bacteria in sputum samples of children with community-acquired pneumonia". *Clinical Microbiology and Infection* 18.3 (2012): 300-307.
10. Grant CC., *et al.* "Risk factors for community-acquired pneumonia in pre-school aged children". *Journal of Paediatrics and Child Health*, 48.5 (2012): 402-412.
11. Bersam FJ., *et al.* "Factors associated with community-acquired pneumonia in hospitalized children and adolescents aged 6 months to 13 years old". *European Journal of Pediatrics* 172.4 (2013): 493-499.
12. Caulfield LE., *et al.* "Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles". *The American Journal of Clinical Nutrition* 80 (2004): 193-198.
13. Tupasi TE., *et al.* "Malnutrition and acute respiratory tract infections in Filipino children". *Reviews of infectious diseases* 12.8 (1990): S1047-1054.
14. Yoon PW., *et al.* "The effect of malnutrition on the risk of diarrheal and respiratory mortality in children <2 years of age in Cebu, Philippines". *The American Journal of Clinical Nutrition* 65 (1997): 1070-1077.
15. Victoria CG., *et al.* "Short-term benefits of catch-up growth for small-for-gestational-age infants". *International Journal of Epidemiology*, 30(2001): 1325-1330.
16. Black RE., *et al.* "Maternal and child undernutrition 1-Maternal and child undernutrition: global and regional exposures and health consequences". *Lancet* 371 (2008): 243-260.
17. Philippine Academy of Pediatric Pulmonologists (PAPP), Inc. (2016). 3rd PAPP update in the evaluation and management of pediatric community-acquired pneumonia. Quezon City, Philippines: 2016 PAPP Task Force on pCAP.

18. Dinur-Schejter Y, *et al.* "Antibiotic treatment of children with community acquired pneumonia: comparison of penicillin or ampicillin versus cefuroxime". *Pediatric Pulmonology* 48 (2013): 52-58.
19. Amarilyo G, *et al.* "IV penicillin G is as effective as IV cefuroxime in treating community-acquired pneumonia in children". *American Journal of Therapeutics* 21.2 (2014): 81-84.
20. Malla L, *et al.* "Comparative effectiveness of injectable penicillin versus a combination of penicillin and gentamicin in children with pneumonia characterized by indrawing in Kenya: a retrospective observational study". *BMJ Open* 7.11 (2017): e019478.
21. World Health Organization (WHO). Basic principles for control of acute respiratory infections in children in developing countries (1986).
22. Nascimento-Carvalho CM, *et al.* "Penicillin/ampicillin efficacy among children with severe pneumonia due to penicillin-resistant pneumococcus". *Journal of Medical Microbiology* 58(2009): 1390-1392.
23. Le Roux DM, *et al.* "Incidence and severity of childhood pneumonia in the first year of life in a South African birth cohort: the Drakenstein Child Health Study". *Lancet Global Health* 3(2015): e95-e103.
24. Leowski J. "Mortality from acute respiratory infections in children under 5 years of age: global estimates". *World Health Stat Q*, 39.2 (1986): 138-144.
25. Casimir GJ, *et al.* "Gender differences in inflammatory markers in children". *Shock*, 33.3 (2010): 258-262.
26. Garenne M. "Sex differences in health indicators among children in African DHS surveys". *Journal of Biosocial Science* 35.4 (2003): 601-614.
27. Martinez FD, *et al.* "Parental smoking enhances bronchial responsiveness in nine-year-old children". *The American Review of Respiratory Disease* 138. 3 (1988): 518-523.
28. Yang Z, *et al.* "Female resistance to pneumonia identifies lung macrophage nitric oxide synthase-3 as a therapeutic target". *eLife* 3(2014): e03711.
29. Lamberti LM, *et al.* "Breastfeeding for reducing the risk of morbidity and mortality in children under two: a systematic literature review and meta-analysis". *BMC Public Health* 13.3 (2013): S18.
30. Lucero MG, *et al.* "Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age". *Cochrane Database Systematic Review* 2009.4 (2009): CD004977.
31. Harboe ZB, *et al.* "Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality". *Clinical Infectious Diseases* 59.8 (2014): 1066-1073.
32. Waight PA, *et al.* "Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study". *The Lancet Infectious Diseases* 15.5 (2018): 535-543.
33. Centers for Disease Control and Prevention (CDC). "Progress toward elimination of Hemophilus influenzae type b invasive disease among infants and children – United States, 1998-2000". *Morbidity and Mortality Weekly Report* 51.11 (2002): 234-237.
34. Cowgill KD, *et al.* "Effectiveness of Hemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya". *JAMA* 296.6(2006): 671-678.
35. Fonseca Lima EJ, *et al.* "Risk factors for community-acquired pneumonia in children under five years of age in the post-pneumococcal conjugate vaccine era in Brazil: a case-control study". *BMC Pediatrics* 16.1 (2016): 157.
36. Gritly SMO, *et al.* "Risk factors of pneumonia among children under 5 years at a pediatric hospital in Sudan". *International Journal of Medical Research and Health Sciences* 7.4 (2018): 60-68.
37. Barson WJ. *Pneumonia in children: epidemiology, pathogenesis, and etiology* (2018).
38. Gutierrez-Ramirez SF, *et al.* "Environmental tobacco smoke and pneumonia in children living in Monterrey, Mexico". *Revista de Salud Pública* (Bogota), 9.1(2007): 76-85.

39. Green GM and Carolin D. "The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages". *The New England Journal of Medicine* 276.8 (1967): 421-427.
40. World Health Organization. Pneumonia (2019).
41. Centers for Disease Control and Prevention (CDC). "Respiratory hygiene/cough etiquette in healthcare settings". (2009).
42. Rahman A., *et al.* "Acute malnutrition in Bangladeshi children: levels and determinants". *Asia Pacific Journal of Public Health* 21.3 (2009): 294-302.
43. Walson JL and Berkley JA. "The impact of malnutrition on childhood infections". *Current Opinion in Infectious Diseases* 31.3 (2018): 231-236.
44. Simbalista R., *et al.* Outcome of children hospitalized with community-acquired pneumonia treated with aqueous penicillin G. *Clinics (Sao Paulo)* 66.1 (2011): 95-100.
45. Queen MA., *et al.* "Comparative effectiveness of empiric antibiotics for community-acquired pneumonia". *Pediatrics* 133.1 (2014): e23-e29.
46. Williams DJ., *et al.* "Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia". *Pediatrics* 132.5 (2013): e1141-e1148.
47. Addo-Yobo, E., *et al.* "Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study". *Lancet* 364.9440 (2004): 1141-1148.
48. Tiewsoh K., *et al.* "Factors determining the outcome of children hospitalized with severe pneumonia". *BMC Pediatrics* 9(2009): 15.
49. Chisti MJ., *et al.* "Pneumonia in severely malnourished children in developing countries – mortality risk, aetiology and validity of WHO clinical signs: a systematic review". *Tropical Medicine & International Health* 14.10 (2009): 1173-1189.
50. Deranged physiology. Causes of antibiotic treatment failure (2016).
51. Aiken AM., *et al.* "Risk and causes of paediatric hospital-acquired bacteremia in Kilifi District Hospital, Kenya: a prospective cohort study". *Lancet* 378.9808 (2011): 2021-2027.

Volume 2 Issue 12 December 2019

© All rights are reserved by Catherine Grace Q Aparece and Anabella S Oncog.